G23.3
Hypomyelination with atrophy of the basal ganglia and cerebellum
Clinical Classification Guidelines
Inclusion Terms
- H-ABC
- TUBB4A-related neurologic disorders
Medical Intelligence & Overview
Hypomyelination with atrophy of the basal ganglia and cerebellum, also known as H-ABC (Hereditary Ataxia with Basal Ganglia and Cerebellar Atrophy), is a rare neurological disorder characterized by abnormal development and degeneration of specific brain regions. This condition affects myelin—the protective coating around nerve fibers—and leads to progressive motor and neurological deficits. Typically associated with mutations in the TUBB4A gene, H-ABC falls under the category of TUBB4A-related neurologic disorders, impacting movement, coordination, and behavior over time.
Causes & Symptoms
Clinical Causes: Mutations in the TUBB4A gene, which provides instructions for making a protein crucial for the stability and function of microtubules in nerve cells. Inherited genetic patterns, often autosomal dominant, meaning a single copy of the altered gene can cause the disorder. No well-established environmental causes have been identified for H-ABC; it is primarily genetic in origin.
Key Symptoms: Progressive loss of motor coordination and balance leading to difficulty walking. Muscle stiffness or rigidity, which can impair movement. Delayed developmental milestones in children, such as sitting, standing, and walking. Dystonia or abnormal muscle contractions causing twisting or repetitive movements. Speech and swallowing difficulties as the condition advances. Cognitive decline or behavioral changes in some cases. Nystagmus or involuntary eye movements. Deterioration of muscle strength and coordination over time.
Diagnostic & Treatment
Diagnosis Path: The diagnosis of H-ABC involves a combination of clinical assessments, neuroimaging, and genetic testing: - **Neurological Examination:** To evaluate motor skills, coordination, reflexes, and muscular tone. - **Magnetic Resonance Imaging (MRI):** Reveals characteristic features such as atrophy of the basal ganglia and cerebellum, along with abnormal myelination patterns. - **Genetic Testing:** Confirms mutations in the TUBB4A gene which are associated with this disorder. - **Family History Assessment:** To identify inherited patterns and provide genetic counseling options.
Treatment Protocols: Currently, there is no cure for hypomyelination with atrophy of the basal ganglia and cerebellum. Treatment strategies focus on managing symptoms and improving quality of life: - **Physical therapy:** To enhance mobility, strength, and coordination. - **Occupational therapy:** Assists in maintaining independence in daily activities. - **Speech therapy:** Addresses communication challenges and swallowing difficulties. - **Medications:** May include spasticity reducers or medications targeting specific symptoms, as prescribed by a healthcare professional. - **Supportive care:** Including nutritional support and adaptive devices to facilitate daily functioning. - **Monitoring and multidisciplinary care:** Regular follow-up with neurology, genetics, and rehabilitation specialists to adapt care plans as the condition progresses.
Clinical Advice & FAQs
Billing Guidance
Is G23.3 a billable ICD-10 code?
Yes, G23.3 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report G23.3?
Clinical documentation must specify the nature of Hypomyelination with atrophy of the basal ganglia and cerebellum and any associated comorbidities for accurate reporting.
Cite this Clinical Reference